Clinical and sociodemographic profile of patients with cutaneous melanoma attended at an oncology referral hospital in Florianópolis between 2013 and 2017

ABSTRACT

Introduction: Cutaneous melanoma is the most lethal skin cancer and its incidence has significantly increased in recent years. In particular, Florianópolis is the Brazilian capital with the highest incidence of the disease.

Objective: To investigate the clinical and sociodemographic profile of patients with cutaneous melanoma treated at a public oncology referral hospital in Florianópolis from 2013 to 2017.

Methods: This is a descriptive and cross-sectional study carried out at the Santa Catarina Oncology Research Center (Centro de Pesquisas Oncológicas - CEPON). It included 468 patients diagnosed with melanoma skin cancer (ICD-O, 3^rd edition C44 - skin melanoma) evaluated between 2013 and 2017. Data collection was performed by accessing the hospital cancer registry and electronic and physical medical records. The data were plotted in a Windows Excel spreadsheet and analyzed using the Statistical Package for the Social Sciences (SPSS) software.

Results: There was a slight predominance of females, white-skinned, with a mean age of 54.3 years old at the time of diagnosis. The most prevalent primary tumor site was the trunk. Superficial spreading melanoma was the most frequent condition, and ulceration was absent in most cases. Clinical stage IV was the most common, and lungs and bronchi were the main metastasis sites. The most performed treatment was wide local excision and the most widely used systemic therapy was chemotherapy.

Conclusion: This study characterized the sociodemographic and clinical profile of patients diagnosed with cutaneous melanoma and treated at a referral hospital in the Brazilian capital with the highest skin cancer rates.

RESUMO

Introdução: O melanoma cutâneo é o câncer de pele mais letal e sua incidência tem aumentado significativamente nos últimos anos. Em particular, Florianópolis é a capital brasileira com maior incidência da doença.

Objetivo: Investigar o perfil clínico e sociodemográfico dos pacientes com melanoma cutâneo atendidos em um hospital público de referência em oncologia de Florianópolis, no período de 2013 a 2017.

Métodos: Trata-se de um estudo descritivo e transversal realizado no Centro de Pesquisas Oncológicas de Santa Catarina (Centro de Pesquisas Oncológicas - CEPON). Foram incluídos 468 pacientes com diagnóstico de câncer de pele melanoma (CID-O, 3^a edição C44 - melanoma de pele) avaliados entre 2013 e 2017. A coleta de dados foi realizada por meio do acesso ao registro hospitalar de câncer e prontuários eletrônicos e físicos. Os dados foram plotados em planilha do Windows Excel e analisados no software Statistical Package for the Social Sciences (SPSS).

Resultados: Houve discreta predominância do sexo feminino, de cor branca, com média de idade de 54,3 anos no momento do diagnóstico. O sítio de tumor primário mais prevalente foi o tronco. O melanoma de disseminação superficial foi a condição mais frequente e a ulceração esteve ausente na maioria dos casos. O estágio clínico IV foi o mais comum, sendo os pulmões e os brônquios os principais sítios de metástase. O tratamento mais realizado foi a excisão local ampla e a terapia sistêmica mais utilizada foi a quimioterapia.

Conclusão: Este estudo caracterizou o perfil sociodemográfico e clínico dos pacientes diagnosticados com melanoma cutâneo e atendidos em um hospital de referência da capital brasileira com as maiores taxas de câncer de pele.

Keywords:

Melanoma - Skin neoplasms - Health profile

Descritores:

Melanoma - Neoplasias da pele - Perfil de saúde

Publication History

Received: 27 August 2021

Accepted: 24 September 2021

Article published online:
22 February 2022

• REFERÊNCIAS

• 1 American Cancer Society (ACS). Cancer facts & figures 2019. Atlanta: ACS; 2019
• 2 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019; Jan; 69: 7-34
• 3 Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA). Estimativa 2020: incidência de câncer no Brasil [Internet]. Rio de Janeiro: INCA; 2019. ;[acesso em 2020 Jul 01]. Available from: https://www.inca.gov.br/estimativa
• 4 Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol 1988; Jun; 124 (06) 869-871
• 5 O'Neill CH, Scoggins CR. Melanoma. J Surg Oncol 2019; Oct; 120 (05) 873-881 https://doi.org/10.1002/jso.25604
• 6 Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV. et al. Signatures of mutational processes in human cancer. Nature 2013; Aug; 500: 415-421
• 7 Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP. et al. A landscape of driver mutations in melanoma. Cell 2012; Jul; 150 (02) 251-263
• 8 Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A. et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 2012; May; 485: 502-506
• 9 Parkin DM, Mesher D, Sasieni P. Cancers attributable to solar (ultraviolet) radiation exposure in the UK in 2010. Br J Cancer 2011; 105 (Suppl 2): S66-S69
• 10 Instituto Brasileiro de Geografia e Estatística (IBGE). Censo demográfico 2020 [Internet]. Brasília (DF): IBGE; 2020. ;[access in 2020 Oct 04]. Available from: http://tabnet.datasus.gov.br/
• 11 Naser N. Melanoma cutâneo: estudo epidemiológico de 30 anos em cidade do sul do Brasil, de 19802009. An Bras Dermatol 2011; Oct; 86 (05) 932-941 https://doi.org/10.1590/S0365-05962011000500011
• 12 Lima AS, Stein CE, Casemiro KP. et al. Epidemiology of melanoma in the South of Brazil: study of a city in the Vale do Itajaí from 1999 to 2013. An Bras Dermatol 2015; Mar/Apr; 90 (02) 185-189
• 13 Dimatos DC, Duarte FO, Vieira VJ, Vasconcellos ZAZ, Bins-Ely J, Neves RD. Melanoma cutâneo no Brasil. Arq Catarin Med 2009; 38 (Suppl 1): 14-19
• 14 Battisti R, Nunes DH, Weber AL, Schweitzer LC, Sgrott I. Avaliação do perfil epidemiológico e da mortalidade dos pacientes com diagnóstico de melanoma cutâneo primário no município de Florianópolis - SC, Brasil. An Bras Dermatol 2009; 84 (04) 335-342 https://doi.org/10.1590/S0365-05962009000400003
• 15 Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970; Nov; 172 (05) 902-908
• 16 Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK. et al. AJCC cancer staging manual. 8th . New York: Springer;; 2017
• 17 Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2010; Apr; 102 (07) 493-501
• 18 Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D. et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015; Jan; 372 (01) 30-39
• 19 Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell 2015; Jun; 161 (07) 1681-1696
• 20 National Comprehensive Cancer Network (NCCN). Guideline for patients - melanoma [Internet]. Plymouth Meeting: NCCN; 2021. ;[access in 2020 Oct 04]. Available from: https://www.nccn.org/patients/guidelines/content/PDF/melanoma-patient.pdf
• 21 Melo AC, Wainstein AJA, Buzaid AC, Thuler LCS. Melanoma signature in Brazil: epidemiology, incidence, mortality, and trend lessons from a continental mixed population country in the past 15 years. Melanoma Res 2018; Dec; 28 (06) 629-636 https://doi.org/10.1097/CMR.0000000000000511
• 22 Wainstein AJA, Neto JPD, Enokihara MY. et al. Demographic, clinical, and pathologic features of patients with cutaneous melanoma: final analysis of the Brazilian Melanoma Group Database. JCO Glob Oncol 2020; Apr; 6: 575-582
• 23 Foiato TF, Bereza BRK, Montenegro MF, Guilherme MR, Volski LB, Rebolho JC. Analysis of patients diagnosed with primary cutaneous melanoma in the last six years in Hospital Erasto Gaertner: epidemiologic profile. An Bras Dermatol 2018; May/Jun; 93 (03) 332-336
• 24 Paulson KG, Gupta D, Kim TS, Veatch JR, Byrd DR, Bhatia S. et al. Age-specific incidence of melanoma in the United States. JAMA Dermatol 2020; Nov; 156 (01) 57-64 https://doi.org/10.1001/jamadermatol.2019.3353
• 25 Ferreira T, Santos IDAO, Oliveira AF, Ferreira LM. Estudo retrospectivo dos pacientes portadores de melanoma cutâneo atendidos na Universidade Federal de São Paulo. Rev Col Bras Cir 2018; Aug; 45 (04) e1715 https://doi.org/10.1590/0100-6991e-20181715
• 26 Costa LMM, Crovador CS, Carvalho CEB, Vazquez VL. Characteristics of Brazilian melanomas: real-world results before and after the introduction of new therapies. BMC Res Notes 2019; May; 12 (01) 296 https://doi.org/10.1186/s13104-019-4336-7
• 27 Olsen CM, Pandeya N, Thompson BS, Dusingize JC, Green AC, Neale RE. et al. Association between phenotypic characteristics and melanoma in a large prospective cohort study. J Invest Dermatol 2019; Mar; 139 (03) 665-672 https://doi.org/10.1016/j.jid.2018.09.022
• 28 Perera E, Gnaneswaran N, Jennens R, Sinclair R. Malignant melanoma. Healthcare (Basel) 2013; Dec; 2 (01) 1-19 https://doi.org/10.3390/healthcare2010001
• 29 Vazquez VL, Silva TB, Vieira MA, Oliveira ATT, Lisboa MV, Andrade DAP. et al. Melanoma characteristics in Brazil: demographics, treatment, and survival analysis. BMC Res Notes 2015; Jan; 8: 4 https://doi.org/10.1186/s13104-015-0972-8
• 30 Tomizuka T, Namikawa K, Higashi T. Characteristics of melanoma in Japan: a nationwide registry analysis 2011-2013. Melanoma Res 2017; Oct; 27 (05) 492-497 https://doi.org/10.1097/CMR.0000000000000375
• 31 Loria D, Abriata MG, Santoro F, Latorre C. Cutaneous melanoma in Argentina: an analysis of its characteristics and regional diferences. Ecancer 2020; Mar; 14: 1017 https://doi.org/10.3332/ecancer.2020.1017
• 32 Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S. et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med 2018; May; 378 (19) 1789-1801 https://doi.org/10.1056/NEJMoa1802357
• 33 Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wokchok JD, Schmidt H. et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 2015; May; 16 (05) 522-530 https://doi.org/10.1016/S1470-2045(15)70122-1
• 34 Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey L. et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 2017; Nov; 377 (19) 1824-1835 https://doi.org/10.1056/NEJMoa1709030